# Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

> **NCT05029063** · PHASE3 · RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 1828 (estimated)

## Conditions studied

- Venous Thromboembolism
- Cancer

## Interventions

- **DRUG:** Rivaroxaban 10 MG

## Key facts

- **NCT ID:** NCT05029063
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-05
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 1828 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029063, "Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05029063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*